September 19, 2024
French Biotech Brenus Pharma Raises € 22M in Series A to Advance Treatment Technology for Cancer Immunotherapy
Issoire, France -
Brenus Pharma, a biotech company has raised € 22 million in its Series A funding round. The company specializes in allogeneic cancer immunotherapies and aims to use the proceeds to further its innovative cancer treatment technology. Leading the round were Angelor, Crédit Agricole Centre-Est, and other prominent investors, including Jacques Gardette, Investsud, Meusinvest (Noshaq), and UI Investissement. The financing closed on September 18, 2024, marks a significant milestone for Brenus Pharma as it plans to accelerate clinical trials of its flagship product, the STC-1010 cancer vaccine.
About the company
Brenus Pharma, founded in 2014, has developed a unique platform that aims to harness the power of the patient's immune system to prevent cancer resistance and progression. Its lead product, STC-1010, is a cancer vaccine designed for patients with metastatical colorectal cancer (mCRC), particularly those resistant to immunotherapies. The platform, known as STC (Stimulated-Tumor-(ghost)-Cells), provides a novel approach to cancer therapy by mimicking the conditions that allow tumor cells to evade the immune system.
Purpose of financing
The funds will also enable the company to expand its research into additional tumor types, such as pancreatic and liver cancers, and to advance its second candidate, STC-1020, through the preclinical stage. Brenus Pharma is positioning itself as a leader in next-generation cancer immunotherapies, and the new funding will be instrumental in achieving that goal.
What the company’s official has to add
“Brenus Pharma has taken a major step forward. The arrival of investment professionals confirms the interest we are arousing. After the creation and sale of Biocorp to Novo Nordisk in 2023, Brenus Pharma now has our full attention to help the company achieve its ambitious goals,”
—- said, Jacques Gardette, co-founder and one of the lead investors
“This funding is a pivotal moment for Brenus Pharma and validates the potential of our STC platform. With solid preclinical results and a strong team, we are confident in our ability to bring a new therapeutic solution to patients,” He added that the company’s ambition is to establish itself on both national and international stages in cancer immunotherapy.
—- expressed Paul Bravetti, CEO of Brenus Pharma
What the investors have to comment
“We are delighted to support Brenus Pharma’s development of cutting-edge technology and look forward to the impact it will have on patients.”
—- Hélène Sabatel, Investment Manager at Noshaq, expressed her excitement about the Franco-Belgian collaboration.
Conclusion
The investment also includes backing from Belgian funds Noshaq and Investsud, further strengthening Brenus Pharma’s ties to the Liège region, where it plans to open an R&D branch. With this latest round of funding, Brenus Pharma is well-equipped to accelerate its mission to revolutionize cancer treatment and improve patient outcomes.
Linkedin